Verrica Pharmaceuticals Inc (NASDAQ:VRCA) COO Linda Palczuk acquired 2,500 shares of the company’s stock in a transaction on Monday, September 17th. The stock was purchased at an average cost of $16.52 per share, for a total transaction of $41,300.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

NASDAQ:VRCA traded up $0.74 during trading hours on Friday, reaching $13.95. 47,743 shares of the company’s stock were exchanged, compared to its average volume of 67,740. Verrica Pharmaceuticals Inc has a 1-year low of $13.00 and a 1-year high of $23.29.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its quarterly earnings results on Tuesday, August 7th. The company reported ($1.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.76). As a group, research analysts expect that Verrica Pharmaceuticals Inc will post -1.15 earnings per share for the current fiscal year.

Several research analysts have recently issued reports on the stock. Bank of America assumed coverage on shares of Verrica Pharmaceuticals in a report on Tuesday, July 10th. They issued a “buy” rating and a $26.00 target price for the company. Zacks Investment Research cut shares of Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, September 20th. Cowen assumed coverage on shares of Verrica Pharmaceuticals in a report on Tuesday, July 10th. They issued an “outperform” rating and a $35.00 target price for the company. Finally, Jefferies Financial Group assumed coverage on shares of Verrica Pharmaceuticals in a report on Tuesday, July 10th. They issued a “buy” rating and a $24.00 target price for the company.

Large investors have recently modified their holdings of the stock. Capital Investment Advisory Services LLC acquired a new stake in Verrica Pharmaceuticals during the 2nd quarter worth $211,000. Laurion Capital Management LP acquired a new stake in Verrica Pharmaceuticals during the 2nd quarter worth $395,000. Dean Capital Investments Management LLC acquired a new stake in Verrica Pharmaceuticals during the 2nd quarter worth $676,000. Asymmetry Capital Management L.P. acquired a new stake in Verrica Pharmaceuticals during the 2nd quarter worth $1,184,000. Finally, Kornitzer Capital Management Inc. KS acquired a new stake in Verrica Pharmaceuticals during the 2nd quarter worth $2,905,000. Hedge funds and other institutional investors own 31.86% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals, Inc operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris.

Recommended Story: Hedge Funds – Risk or Reward?

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.